首页> 外文期刊>European journal of pain : >The Adjective Rating Scale for Withdrawal: Validation of its ability to assess severity of prescription opioid misuse
【24h】

The Adjective Rating Scale for Withdrawal: Validation of its ability to assess severity of prescription opioid misuse

机译:退出的形容词评级规模:验证其评估处方阿片类药物滥用严重程度的能力

获取原文
获取原文并翻译 | 示例
           

摘要

Background Withdrawal symptoms have been widely shown to be a useful indicator of the severity of opioid dependence. One of the most used instruments to assess them is the Adjective Rating Scale for Withdrawal (ARSW). However, there is a lack of adaptations and validations for its use with prescription opioids, even less for chronic pain patients under treatment with these analgesics. Thus, the aims of this study were to analyse the psychometric properties and invariance across gender of the ARSW in a sample of chronic noncancer pain patients. Methods Data were collected from 208 consumers of opioid medication, chronic noncancer pain patients. Participants completed sociodemographic, ARSW, prescription opioid dependence (DSM-IV-TR) and prescription opioid-use disorder (DSM-5) measurements. Gender invariance was assessed through multigroup confirmatory factor analysis (CFA). Results The ARSW showed a unidimensional factor structure and high internal consistency (Cronbach's alpha = 0.85). Multigroup CFA showed configural, metric, scalar and strict invariances of ARSW across gender. Predictive validity analyses indicated that ARSW has good capacity for identifying the severity of prescription opioid-use disorder, using both DSM-IV-TR and DSM-5 criteria. Conclusions These findings show that the ARSW is a valid and reliable tool for use in the assessment of the withdrawal of prescription opioids in chronic pain patients under treatment with these analgesics, regardless of their gender. Significance Findings supported the reliability and validity of the ARSW to assess withdrawal of prescription opioids in individuals with chronic noncancer pain. The instrument can be applied indistinctly in men and women. An increase in the ARSW scores could be used as an indicator of potential risk of prescription opioid-use disorder during long-term treatments.
机译:背景技术戒断症状已被广泛显示是阿片类药物依赖性严重程度的有用指标。评估它们的最常用仪器之一是退出(ARSW)的形容词评级规模。然而,缺乏适应和验证的配方阿片类药物,甚至少于用这些镇痛药治疗的慢性疼痛患者的适应性和验证。因此,本研究的目的是分析慢性非癌症患者样本中ARSW的性别的心理学性质和不变性。方法采用阿片类药物的208名消费者,慢性非癌症患者收集数据。参与者完成了社会碘目,ARSW,处方阿片类药物依赖(DSM-IV-TR)和处方阿片类药物障碍(DSM-5)测量。通过Multigroup确认因素分析(CFA)评估性别不变性。结果ARSW显示了一个单向因子结构和高内部一致性(Cronbach的alpha = 0.85)。 MultiGroup CFA在性别中显示了配置,指标,标量和严格的ARSW修正。预测有效性分析表明,使用DSM-IV-TR和DSM-5标准,ARSW具有良好的能力识别处方阿片类药物使用障碍的严重程度。结论这些研究结果表明,ARSW是用于评估慢性疼痛患者在慢性疼痛患者的处方阿片类药物撤离的有效可靠的工具,无论其性别如何。意义调查结果支持ARSW的可靠性和有效性,以评估具有慢性非癌症疼痛的个体中的处方阿片类药物。仪器可以毫不含量地应用于男性和女性。 ARSW评分的增加可用作长期治疗期间处方阿片类药物障碍潜在风险的指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号